Inhibition of PARP1 is a clinically effective synthetic lethal therapy in homologous recombination (HR)‐deficient cancers by generating double‐strand breaks (DSBs).[1] However, it offers insubstantial benefits for the majority of cancer types that are HR‐proficient, such as nonsmall cell lung cancer (NSCLC). This evidence concerns the gene PARP1 and cancer.